Announcement of Appointment of Representative Director and Executive Officer COO at Blue Industries Inc.

Blue Industries Inc. (Headquarters: 1-2-1 Kinshicho, Sumida-ku, Tokyo, Ark Central 14F; Representative Director: Ryusuke Kuji) announces that Ryusuke Kuji (Kuji Ryusuke) has been appointed as Representative Director, and Masakazu Toda (Toda Masakazu) has been appointed as Executive Officer and Chief Operating Officer (COO). Under this new management structure, the company will further accelerate the promotion and business expansion of its 'at-home cancer risk screening' service.

From left in the photo: Representative Director Ryusuke Kuji, COO Masakazu Toda

【Background of the Appointments】

Japan's low cancer screening participation rate has long been a challenge. While many lives are lost due to late detection, psychological and physical barriers to testing remain high, leaving many people unable to access screening despite their desire to do so.

Blue Industries Inc. has developed and provided a test kit that enables high-precision screening for seven types of cancer—pancreatic, liver, lung, uterine, colorectal, breast, and prostate—by simply collecting urine at home and sending it for analysis. The AI analyzes microRNA contained within urinary exosomes to assess cancer risk.

Among major domestic competitors, the company holds a differentiated R&D foundation as the only provider capable of site-specific detection for liver and uterine cancers.

With this announcement, Ryusuke Kuji, who has led research and development since the company's founding, assumes the role of Representative Director. Simultaneously, Masakazu Toda, who brings extensive experience in the global healthcare sector, joins as Executive Officer COO. Together, they will establish an integrated management structure that unifies R&D with business execution. Under this new leadership, the company aims to strengthen research collaborations and deliver accessible options for early cancer detection to society.

Representative Director Ryusuke Kuji

【Comment on the Appointment】

There is no downside to early cancer detection. Guided by our belief to 'deeply understand our users and sincerely deliver valuable solutions,' we aim to create a future where everyone can truly understand their body and live a fulfilling life through our services. We will continue to be a scientifically grounded and execution-driven company, sincerely giving back to our stakeholders.

【Profile】

Joined the company in its early stages. Initially worked on developing biosensing devices by applying expertise in mechanical engineering. Leveraged research experience in arteriosclerosis from a university lab to contribute to the launch of the company's core business. Later served as an executive overseeing all departments, gaining diverse experience in operations, sales, back-office functions, and fundraising before assuming his current role.

Executive Officer (COO) Masakazu Toda

【Comment on the Appointment】

'We will connect Blue Industries' advanced R&D foundation to real-world implementation and build a business that widely delivers new options for early cancer detection.'

【Profile】

Began his career in sales for pharmaceutical products at Takeda Pharmaceutical Company Limited, where he spent years planning and executing sales strategies. Subsequently served as COO of Aker BioMarine Japan, a global healthcare company headquartered in Europe, leading the launch and growth of its Japanese operations. Held executive roles at TCB Tokyo Central Aesthetic Surgery Group and a healthtech company in the medical device sector. Appointed Executive Officer COO of Blue Industries Inc. in April 2026.

【Future Outlook】

Under the new management structure, Blue Industries Inc. will advance its business according to the following principles:

Accelerated Decision-Making and Business Scaling: Establish a robust management framework led by the CEO and COO to aggressively promote product awareness and expand distribution channels.

Enhanced Scientific Communication and Trust: Launch full-scale scientific outreach based on evidence, accelerating deployment to medical institutions, health insurers, and corporate employee welfare programs.

【Business Overview】

Blue Industries Inc.'s core business is the manufacturing and sales of the at-home cancer risk screening kit 'bluedrop (BlueDrop).' Utilizing proprietary AI technology to analyze microRNA within urinary exosomes, the company aims to deliver high-accuracy cancer risk assessment without requiring visits to medical facilities.

A lab designed and newly established specifically for the company's analytical operations

【bluedrop】

bluedrop is an at-home cancer risk screening service that is completed simply by collecting urine and sending it via a dedicated kit. The company's proprietary AI analyzes microRNA within urinary exosomes to evaluate cancer risk for the following seven types:

Test results can be viewed via smartphone.

bluedrop Test Kit

Targeted Cancers (7 types): Pancreatic cancer, liver cancer, lung cancer, uterine cancer, colorectal cancer, breast cancer, prostate cancer

Notably, Blue Industries is the only company among major domestic competitors capable of site-specific detection for liver and uterine cancers. Additionally, the non-invasive urine collection method allows painless, at-home testing, enabling users to monitor changes in cancer risk over time through repeated testing.

Site-specific evaluation of 7 types of cancer risk

＜Key Features＞

- Simultaneous, site-specific assessment of 7 cancer risks

- Non-invasive testing completed at home (urine collection only)

- High accuracy through AI × microRNA analysis

- Unique coverage: Only major product in Japan capable of detecting liver and uterine cancers

Learn more

■ About Blue Industries Inc.

Mission: 'Transform life information into personal assets and societal strength.' The company offers an accessible at-home 'cancer risk screening' service. By analyzing microRNA within exosomes found in urine, it screens for seven types of cancer—pancreatic, liver, lung, uterine, colorectal, breast, and prostate—by specific site. By providing opportunities for early disease detection, the company contributes to reducing physical and economic burdens and enhancing the richness of life.

■ Company Overview

Company Name: Blue Industries Inc.

Representative: Representative Director Ryusuke Kuji

Founded: August 2015

Headquarters: 1-2-1 Kinshicho, Sumida-ku, Tokyo, Ark Central 14F

Website: https://www.blueindustries.co.jp/

Business: Manufacturing and sales of at-home cancer risk screening kits; development of cancer risk assessment systems using microRNA analysis and AI